TY - JOUR
T1 - Update on Nephrogenic Systemic Fibrosis
AU - Thomsen, Henrik S.
AU - Marckmann, Peter
AU - Logager, Vibeke B.
PY - 2008/11/1
Y1 - 2008/11/1
N2 - Gadolinium-based contrast agents were for many years considered safe, but this is no longer the case. The least stable agents may trigger the development of nephrogenic systemic fibrosis (NSF), a generalized fibrotic disorder, in renal failure patients. The use of gadodiamide and gadopentetate dimeglumine is now contraindicated in Europe and Japan in patients who have a glomerular filtration rate less than 30 mL/min/1.73 m2, including those on dialysis. The fear of NSF, however, should not lead to an enhanced MR imaging examination being denied when there is a good clinical indication to give a gadolinium-based contrast agent.
AB - Gadolinium-based contrast agents were for many years considered safe, but this is no longer the case. The least stable agents may trigger the development of nephrogenic systemic fibrosis (NSF), a generalized fibrotic disorder, in renal failure patients. The use of gadodiamide and gadopentetate dimeglumine is now contraindicated in Europe and Japan in patients who have a glomerular filtration rate less than 30 mL/min/1.73 m2, including those on dialysis. The fear of NSF, however, should not lead to an enhanced MR imaging examination being denied when there is a good clinical indication to give a gadolinium-based contrast agent.
KW - Gadolinium-based contrast agents
KW - Late adverse reactions
KW - Nephrogenic systemic fibrosis
UR - http://www.scopus.com/inward/record.url?scp=52949102596&partnerID=8YFLogxK
U2 - 10.1016/j.mric.2008.07.011
DO - 10.1016/j.mric.2008.07.011
M3 - Review
C2 - 18926421
AN - SCOPUS:52949102596
SN - 1064-9689
VL - 16
SP - 551
EP - 560
JO - Magnetic Resonance Imaging Clinics of North America
JF - Magnetic Resonance Imaging Clinics of North America
IS - 4
ER -